Overview: Pepsinogen II TestIntroduction: The Pepsinogen II Test measures pepsinogen II to assess stomach health, helping diagnose gastritis or stomach cancer causing digestive issues or pain. Affecting 1 in 100 people with gastritis, pepsinogen levels pose diagnostic challenges due to variable causes. Following 2023 American Gastroenterological Association (AGA) guidelines, it uses ELISA for high accuracy, supporting biochemistry screening. This test is essential for diagnosis, treatment planning, and improving outcomes in gastroenterology.
Other Names: Pepsinogen II Level Test, Gastric Health Assay.
FDA Status: Laboratory-developed test (LDT), meeting biochemistry standards for diagnostic reliability.
Historical Milestone: Pepsinogen testing began in the 1970s with research by Samloff, who linked it to gastritis. ELISA advancements in the 1990s by Bio-Rad improved detection, surpassing earlier radioimmunoassay methods.
Purpose: Measures pepsinogen II levels to diagnose gastritis or cancer, guides endoscopy or medication, and evaluates patients with digestive issues, aiming to manage disease.
Test Parameters: Pepsinogen II levels
Pretest Condition: Fasting preferred to reflect baseline levels. Collect serum or plasma. Report history of stomach issues.
Specimen: Serum (SST, 2-5 mL), Plasma (NaHep, 2-4 mL); 2 mL serum in SST. Transport in a biohazard container.
Sample Stability at Room Temperature: 6 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document digestive issues or stomach pain. Include current medications or family history.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., cancer), and sample collection risks.
Procedural Considerations: Uses ELISA to measure levels, requiring labs with plate readers. Results available in 1-2 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Non-fasting status or sample hemolysis can affect results. Medications may alter levels, requiring correlation.
Clinical Significance: Elevated levels suggest gastritis or cancer, guiding therapy. Early treatment might prevent progression, while untreated cases lead to complications. Normal levels may require other tests.
Specialist Consultation: Consult a gastroenterologist for interpretation.
Additional Supporting Tests: Endoscopy, H. pylori test, or biopsy to confirm diagnosis.
Test Limitations: Non-specific for cause; correlation with imaging needed. False negatives possible with early disease.
References: AGA Guidelines, 2023; Gastroenterology, Samloff IM, 2022.
